Literature DB >> 19331146

Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells.

Arpad Szanto1, Zita Bognar, Andras Szigeti, Aliz Szabo, Laszlo Farkas, Ferenc Gallyas.   

Abstract

BACKGROUND: Taxol is the most commonly used agent for salvage chemotherapy in transitional cell carcinoma of the urothelium. We examined mechanisms responsible for taxol resistance by using T24 human bladder carcinoma cells.
MATERIALS AND METHODS: We used an inhibitor and an activator of the phosphatidylinositol-3 kinase-Akt pathway in cell survival and caspase-3 assays, an HPLC method for determining released cytochrome c and immunoblotting for detecting protein phosphorylation.
RESULTS: Activation of Akt increased paclitaxel resistance by increasing Bad phosphorylation, leading to decreased release of mitochondrial cytochrome c and caspase-3-mediated apoptosis. On the other hand, inhibition of Akt prevented paclitaxel resistance by enhancing the effects of paclitaxel on Bad phosphorylation, mitochondrial cytochrome c release and caspase-3-mediated apoptosis, besides diminishing or abolishing the opposing effects of Akt activation.
CONCLUSION: Akt-mediated Bad phosphorylation plays an important role in preservation of mitochondrial membrane systems leading to paclitaxel resistance in T24 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331146

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Prediction of functional phosphorylation sites by incorporating evolutionary information.

Authors:  Shen Niu; Zhen Wang; Dongya Ge; Guoqing Zhang; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

2.  Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.

Authors:  Harika Sabbineni; Abdulrahman Alwhaibi; Anna Goc; Fei Gao; Alanna Pruitt; Payaningal R Somanath
Journal:  Eur J Pharmacol       Date:  2015-07-03       Impact factor: 4.432

3.  The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

Authors:  Hye Sook Chon; Douglas C Marchion; Yin Xiong; Ning Chen; Elona Bicaku; Xiaomang Ba Stickles; Nadim Bou Zgheib; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Johnathan M Lancaster
Journal:  Gynecol Oncol       Date:  2011-10-26       Impact factor: 5.482

4.  AIEgen-based theranostic system: targeted imaging of cancer cells and adjuvant amplification of antitumor efficacy of paclitaxel.

Authors:  Chao Chen; Zhegang Song; Xiaoyan Zheng; Zikai He; Bin Liu; Xuhui Huang; Deling Kong; Dan Ding; Ben Zhong Tang
Journal:  Chem Sci       Date:  2016-12-02       Impact factor: 9.825

5.  Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.

Authors:  Balazs Radnai; Csenge Antus; Boglarka Racz; Peter Engelmann; Janos Krisztian Priber; Zsuzsanna Tucsek; Balazs Veres; Zsuzsanna Turi; Tamas Lorand; Balazs Sumegi; Ferenc Gallyas
Journal:  Mol Cancer       Date:  2012-05-14       Impact factor: 27.401

6.  Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing

Authors:  Moureq R Alotaibi; Zeinab K Hassan; Salim S Al-Rejaie; Musaad A Alshammari; Mashal M Almutairi; Ali R Alhoshani; Wael A Alanazi; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

Review 7.  Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs.

Authors:  Yusif M Mukhtar; Michael Adu-Frimpong; Ximing Xu; Jiangnan Yu
Journal:  Biosci Rep       Date:  2018-11-13       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.